Search Follow us


We are initiating coverage on ASLAN Pharmaceuticals, a clinical-stage drug developer focusing on in-licensing drugs with a high prevalence in Asia that are orphan indications in the West. The company’s lead asset is the pan-HER inhibitor varlitinib, which is in clinical trials for biliary tract cancer (BTC, pivotal) and gastric cancer (GC, Phase II/III), both of which are widely prevalent in Asia. The company has also planned a Phase II trial of ASLAN003 targeting AML via the novel mechanism of inducing blast differentiation. We initiate at NT$9.5bn or NT$72.87 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs